Canadian Manufacturing

Teva Canada announces product availability of AJOVY

AJOVY offers quarterly or monthly dosing regimens for the preventive treatment of migraine

August 19, 2020  by CM Staff

Teva Canada announces product availability of AJOVY™ (fremanezumab) (PHOTO: Teva Canada)

MONTRÉAL — Teva Canada, a subsidiary of Teva Pharmaceutical Industries Ltd., announced product availability of AJOVY (fremanezumab) 225 mg solution for subcutaneous injection for the preventive treatment of migraine in adults who have at least four migraine days per month. According to a company statement, AJOVY offers quarterly or monthly dosing regimens for the preventive treatment of migraine. The quarterly dose of 675 mg is given as three 225 mg subcutaneous injections once every three months; the monthly dose of 225 mg is given as one subcutaneous injection once each month.

“Canadian patients and prescribers have been waiting for a product like AJOVY that offers flexible dosing options convenient for their busy lifestyles,” said Christine Poulin, general manager of Teva Canada, in a prepared statement. “With the product now in distribution across Canada, Teva Canada is also introducing a comprehensive patient support program to educate patients and provide financial support to meet the various needs of Canadians who suffer with the condition.”

Migraine is a disabling chronic neurological disease that causes head pain so severe that sufferers often cannot function. Migraine reduces quality of life and disrupts migraineurs’ ability to perform daily activities. It is among the top 10 causes of disability worldwide and the seventh cause of years of life lost to disability. In Canada, migraine is most common in women and most common between the ages of 30 and 49.

AJOVY was evaluated in two Phase III clinical trials that enrolled patients with disabling migraine and studied fremanezumab as a prophylactic treatment. In these trials, efficacy assessments included the change from baseline in the number of average monthly migraine or headache days and the proportion of patients achieving at least a 50% reduction in affected days.

Advertisment

Print this page

Related Stories